Can I use Gemtesa (vibegron) or Mybetriq (mirabegron) for overactive bladder during an active urinary tract infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Do Not Start Gemtesa or Mybetriq During an Active UTI

You should not initiate either Gemtesa (vibegron) or Mybetriq (mirabegron) while a patient has an active urinary tract infection—first treat and resolve the UTI, then start OAB pharmacotherapy. 1

Rationale Based on Guidelines

The 2024 AUA/SUFU guidelines explicitly state that urinalysis should be performed in all patients with OAB symptoms, and urine culture should be obtained if urinalysis suggests infection 1. This is not merely a diagnostic formality—the guideline emphasizes that infection must be excluded before proceeding with OAB treatment 1. The framework is clear: evaluate for UTI first, treat any infection found, then address OAB symptoms.

Why This Matters Clinically

Starting beta-3 agonists during active infection creates several problems:

  • Diagnostic confusion: OAB symptoms (urgency, frequency) overlap substantially with UTI symptoms. You cannot accurately assess baseline OAB severity or treatment response when infection is present.

  • Urinary retention risk: Both Gemtesa and Mybetriq carry warnings about urinary retention 2. This risk is particularly concerning during UTI when bladder inflammation may already compromise voiding. The FDA labeling for Gemtesa specifically warns to monitor for urinary retention and discontinue if it develops 2.

  • Masking infection progression: Beta-3 agonists might partially improve frequency/urgency symptoms, potentially masking inadequate antibiotic response or progression to pyelonephritis.

The Correct Sequence

  1. Obtain urinalysis and culture when OAB symptoms are present 1
  2. Treat the UTI with appropriate antibiotics if infection is confirmed
  3. Reassess symptoms after infection clearance (typically 1-2 weeks post-treatment)
  4. Initiate OAB pharmacotherapy only if urgency, frequency, and urgency incontinence persist after infection resolution 1

Common Pitfall to Avoid

Do not assume all urgency and frequency in a patient with known OAB represents their baseline condition. Always rule out UTI with urinalysis before adjusting or initiating OAB medications 1. Many patients will have complete or near-complete resolution of "OAB symptoms" once the infection is treated, avoiding unnecessary medication exposure.

After UTI Resolution: Choosing Between Gemtesa and Mybetriq

Once infection is cleared, both agents are reasonable first-line options. Recent evidence suggests vibegron (Gemtesa) may have slight advantages in reducing urgency incontinence episodes and improving voided volumes compared to mirabegron 3, 4, though both are effective 5. Vibegron also has higher beta-3 receptor selectivity and lacks significant drug interactions via cytochrome P450 6, which may be advantageous in patients on multiple medications.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.